The Endocrine Society’s annual meeting, ENDO 2026, convened in Chicago, Illinois, serving as the premier global forum for the latest advancements in endocrine research and clinical practice. Bringing together thousands of clinicians, researchers, and students from across the globe, the conference highlighted the evolving landscape of hormone-related health, ranging from pediatric developmental milestones to the complex interplay between metabolic health and reproductive hormones in aging populations. As the field of endocrinology continues to grapple with the dual challenges of rising obesity rates and the demand for personalized medicine, ENDO 2026 provided a critical platform for high-stakes debates and the unveiling of standardized care protocols that will shape the industry for the coming decade.
The Testosterone Debate: Addressing Low Testosterone in the Context of Obesity
One of the most anticipated sessions of the conference focused on a growing clinical dilemma: the management of low testosterone (hypogonadism) in men with obesity. Moderated by former Endocrine Society President Stephen Hammes, MD, PhD, the debate titled "Low Testosterone in Obesity: Should We Treat or Not?" addressed a gap in the current standard of care that has left many practitioners searching for clearer guidance.
The debate featured two prominent figures in the field: Franck Mauvais-Jarvis, MD, PhD, of Tulane University School of Medicine, who argued in favor of pharmacological treatment, and David Handelsman, MBBS, PhD, FRACP, of the ANZAC Research Institute at the University of Sydney, who advocated for a more conservative, lifestyle-first approach.
The core of the controversy lies in the "hypogonadal-obesity cycle." Supporting data suggests that obesity leads to decreased testosterone through several mechanisms, including the conversion of testosterone to estrogen in adipose tissue and the suppression of the hypothalamic-pituitary-gonadal (HPG) axis by inflammatory cytokines. Conversely, low testosterone levels can lead to increased fat mass and decreased muscle mass, making it harder for patients to lose weight through traditional means.
Dr. Mauvais-Jarvis presented the case that testosterone replacement therapy (TRT) can serve as a metabolic catalyst. By improving lean body mass and potentially enhancing insulin sensitivity, TRT may provide the physiological boost necessary for obese men to engage more effectively in physical activity and weight loss efforts. On the opposing side, Dr. Handelsman emphasized the risks of over-medicalization. He argued that since low testosterone in these cases is often a symptom of obesity rather than a primary failure of the testes, the focus should remain on weight loss through diet, exercise, and potentially bariatric surgery or GLP-1 receptor agonists, which can naturally restore testosterone levels without the potential cardiovascular or hematological risks associated with exogenous hormones.
Dr. Hammes noted that the lack of a specific, universally accepted standard of care for this demographic makes such debates essential. The session underscored the necessity for clinicians to weigh the immediate symptomatic benefits of therapy against the long-term goal of metabolic restoration.
Chronology of Clinical Advancements: The 2026 CPP Guideline Release
A landmark moment of the conference occurred on Saturday, June 14, with the official publication and presentation of the "Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline." Published simultaneously in The Journal of Clinical Endocrinology & Metabolism (JCEM), these guidelines represent the first major update in several years for the management of Central Precocious Puberty (CPP).
CPP is characterized by the premature activation of the HPG axis, leading to the development of secondary sexual characteristics before the age of eight in girls and nine in boys. If left untreated, CPP can lead to premature epiphyseal closure, resulting in significantly reduced adult height, as well as profound psychological and social distress for the child.
The new guidelines, discussed in detail by Senior Editor Derek Bagley and the primary authors, provide updated recommendations on:
- Diagnostic Thresholds: Refining the use of GnRH stimulation tests and the interpretation of basal luteinizing hormone (LH) levels.
- Imaging Protocols: Establishing clearer criteria for when brain MRI is necessary to rule out intracranial lesions, particularly in boys and very young girls.
- Treatment Monitoring: Standardizing the use of GnRH analogs and determining the optimal timing for the cessation of therapy to maximize final adult height.
- Psychosocial Support: Integrating mental health assessments into the standard clinical workflow for pediatric patients.
The release of these guidelines is expected to reduce variability in care across different regions and specialties, ensuring that pediatricians and pediatric endocrinologists are aligned in their diagnostic and therapeutic approaches.
Global Collaboration and the Transatlantic Alliance Award
The international nature of the Endocrine Society was highlighted by the presentation of the Transatlantic Alliance Award to Anna L. Gloyn, DPhil, FMedSci. This prestigious award, a joint initiative between the Endocrine Society and the European Society of Endocrinology, recognizes leaders who have made significant contributions to the field on both sides of the Atlantic.
In an interview with Glenda Fauntleroy Shaw, Dr. Gloyn reflected on her extensive career conducting research in both the United Kingdom and the United States. Dr. Gloyn is widely recognized for her work on the genetics of type 2 diabetes and neonatal diabetes, particularly her efforts in translating genetic discoveries into clinical insights.
Dr. Gloyn’s reflections provided a unique look into the sociology of science. She noted that while the fundamental principles of laboratory research remain constant, the "lab culture" often differs based on the Principal Investigator (PI) rather than the country. However, she pointed out distinct social differences, such as the British tradition of post-work socializing at a pub, which contrasted with her experiences in American labs. Her career trajectory serves as a testament to the importance of international mobility in science, allowing researchers to combine the strengths of different institutional frameworks to solve complex biological puzzles.
Historical Impact: ENDO as a Career Catalyst
Beyond the data and clinical guidelines, ENDO 2026 dedicated space to the institutional memory of the society. In a retrospective titled "Looking Back: Unforgettable Moments from ENDOs Past," veteran members shared stories of how the annual meeting served as a turning point in their professional lives.
For many, the meeting is more than a series of lectures; it is a networking hub that fosters lifelong collaborations. One notable anecdote highlighted a former student who decided to specialize in endocrinology after attending their first ENDO meeting, eventually rising to become the President of the Endocrine Society. This emphasis on mentorship and the "human element" of science remains a core pillar of the society’s mission. The 2026 Chicago meeting continued this tradition, offering specialized tracks for early-career investigators and students to interact with global experts.
Analysis of Broader Implications and Future Trends
The themes emerging from ENDO 2026 suggest a significant shift in the field of endocrinology. The debate over testosterone and obesity reflects a broader trend toward "Metabolic Endocrinology," where hormonal health is increasingly viewed through the lens of systemic metabolic function rather than isolated glandular disorders. As the global prevalence of obesity continues to rise, the demand for endocrine-led weight management strategies is expected to grow exponentially.
Furthermore, the release of the CPP guidelines highlights the increasing precision of pediatric endocrinology. With the advent of more sensitive diagnostic tools and a better understanding of the genetic drivers of puberty, clinicians are moving away from "one-size-fits-all" age thresholds toward a more nuanced, individualized assessment of pubertal development.
The recognition of researchers like Dr. Anna Gloyn also signals the field’s commitment to genomic medicine. The transition from identifying genetic variants to understanding their functional impact on hormone secretion is the next frontier in endocrinology, promising a future where treatments for conditions like diabetes and thyroid disorders are tailored to a patient’s specific genetic profile.
Supporting Data and Market Context
The discussions at ENDO 2026 occur against a backdrop of significant economic and demographic shifts. The global market for testosterone replacement therapy, for instance, is projected to reach several billion dollars by the end of the decade, driven largely by aging populations and the obesity epidemic. Similarly, the market for pediatric growth hormones and GnRH analogs is seeing steady growth as diagnostic rates for developmental disorders improve in emerging markets.
The Endocrine Society’s role in providing evidence-based guidelines is crucial in this environment. In an era where "wellness" trends and off-label hormone use are frequently promoted on social media, the Society’s commitment to rigorous peer-reviewed data serves as a vital safeguard for public health.
As ENDO 2026 concluded, the consensus among attendees was clear: the future of endocrinology lies in the integration of diverse disciplines—genetics, metabolism, pediatrics, and geriatric medicine—to provide a holistic approach to human health. The Chicago meeting not only addressed current clinical uncertainties but also laid the groundwork for the next generation of endocrine breakthroughs.
